{"organizations": [], "uuid": "a8df2c03979e87a5ef4f934b8ff9181b93a2c0fd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180503.html", "section_title": "Archive News &amp; Video for Thursday, 03 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/teva-pharm-ind-results/teva-pharm-q1-profit-down-less-than-forecast-raises-2018-outlook-idUSL8N1SA29V", "country": "US", "domain_rank": 408, "title": "Teva Pharm Q1 profit down less than forecast, raises 2018 outlook", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T19:09:00.000+03:00", "replies_count": 0, "uuid": "a8df2c03979e87a5ef4f934b8ff9181b93a2c0fd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/teva-pharm-ind-results/teva-pharm-q1-profit-down-less-than-forecast-raises-2018-outlook-idUSL8N1SA29V", "ord_in_thread": 0, "title": "Teva Pharm Q1 profit down less than forecast, raises 2018 outlook", "locations": [], "entities": {"persons": [{"name": "tova cohen", "sentiment": "none"}, {"name": "ari rabinovitch", "sentiment": "none"}], "locations": [{"name": "israel", "sentiment": "none"}], "organizations": [{"name": "teva pharmaceutical industries", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "teva pharm", "sentiment": "negative"}, {"name": "tel aviv", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "teva", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "TEL AVIV, May 3 (Reuters) - Israel’s heavily indebted Teva Pharmaceutical Industries reported a smaller than-expected drop in first-quarter net profit on Thursday and raised its forecast for full-year earnings.\nThe world’s largest generic drugmaker said it earned 94 cents per share excluding one-time items in the January-March period, down from $1.06 a year earlier. Revenue fell 10 percent to $5.1 billion.\nAnalysts had forecast Teva would earn 67 cents a share ex-items on revenue of $4.8 billion, according to Thomson Reuters I/B/E/S.\nFor the full year it raised its adjusted EPS outlook to $2.40-2.65 from $2.25-2.50. (Reporting by Tova Cohen, Editing by Ari Rabinovitch)\nOur ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-03T19:09:00.000+03:00", "crawled": "2018-05-04T16:47:36.012+03:00", "highlightTitle": ""}